Holen Sie sich die Stockscreener-App
23.15
2.03%
-0.48
Vorhandelsmarkt:
23.15
Schlusskurs vom Vortag:
$23.63
Offen:
$23.5
24-Stunden-Volumen:
1.20M
Relative Volume:
1.19
Marktkapitalisierung:
$1.89B
Einnahmen:
$305.00K
Nettoeinkommen (Verlust:
$-328.98M
KGV:
-5.4276
EPS:
-4.2652
Netto-Cashflow:
$-309.60M
1W Leistung:
+2.71%
1M Leistung:
+6.93%
6M Leistung:
+69.97%
1J Leistung:
+3.90%
1-Tages-Spanne:
$22.70
$23.94
1-Wochen-Bereich:
$22.35
$24.23
52-Wochen-Spanne:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Firmenname
Viridian Therapeutics Inc
Sektor
Branche
Telefon
617.272.4600
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie VRDN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
23.15 | 2.20B | 305.00K | -328.98M | -309.60M | -4.2652 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Eingeleitet | TD Cowen | Buy |
| 2024-09-11 | Bestätigt | Needham | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-05-09 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Eingeleitet | BTIG Research | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-05-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-04-17 | Eingeleitet | Wells Fargo | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2022-12-19 | Eingeleitet | Cowen | Outperform |
| 2022-12-19 | Eingeleitet | Needham | Buy |
| 2022-12-16 | Eingeleitet | Credit Suisse | Outperform |
| 2022-12-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-23 | Eingeleitet | B. Riley Securities | Buy |
| 2021-11-18 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Viridian submits BLA for veligrotug to treat TED - Eyes On Eyecare
Corton Capital Inc. Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
VRDN: BTIG Reiterates 'Buy' Rating and Price Target at $61.00 | - GuruFocus
Chart based analysis of Viridian Therapeutics Inc. trendsQuarterly Trade Review & Consistent Income Trade Ideas - newser.com
Smart tools for monitoring Viridian Therapeutics Inc.’s price action2025 Geopolitical Influence & Real-Time Chart Pattern Alerts - newser.com
Viridian Therapeutics submits Biologics License Application to FDA for veligrotug - Ophthalmology Times
Viridian Therapeutics submits BLA for thyroid disease drug - Traders Union
Viridian Therapeutics (VRDN) Submits BLA for Veligrotug to FDA - GuruFocus
Trend analysis for Viridian Therapeutics Inc. this weekWeekly Risk Report & AI Forecast for Swing Trade Picks - newser.com
Can Viridian Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Pullbacks & Daily Stock Momentum Reports - newser.com
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease - The Joplin Globe
How hedge fund analytics apply to Viridian Therapeutics Inc. stockTrade Ideas & Weekly High Momentum Picks - newser.com
How Viridian Therapeutics Inc. stock reacts to job market dataQuarterly Portfolio Summary & Target Return Focused Picks - newser.com
Can machine learning forecast Viridian Therapeutics Inc. recovery2025 Top Gainers & Weekly High Return Stock Forecasts - newser.com
How buybacks impact Viridian Therapeutics Inc. stock valueJuly 2025 Short Interest & Safe Capital Allocation Plans - newser.com
Can swing trading help recover from Viridian Therapeutics Inc. lossesShare Buyback & Community Consensus Trade Alerts - newser.com
Top chart patterns to watch in Viridian Therapeutics Inc.Rate Cut & High Win Rate Trade Tips - newser.com
Will Viridian Therapeutics Inc. (1S1) stock attract long term capital inflows2025 Key Lessons & Fast Exit and Entry Trade Guides - newser.com
Chart based exit strategy for Viridian Therapeutics Inc.2025 Price Momentum & Weekly High Return Stock Forecasts - newser.com
Why Viridian Therapeutics Inc. (1S1) stock is a must watch tickerWeekly Stock Analysis & Verified Chart Pattern Signals - newser.com
Regression analysis insights on Viridian Therapeutics Inc. performanceDay Trade & Free Verified High Yield Trade Plans - newser.com
Is Viridian Therapeutics Inc. stock attractive for growth ETFsSell Signal & Community Consensus Trade Alerts - newser.com
Oppenheimer Maintains Viridian Therapeutics (VRDN) Outperform Recommendation - MSN
Moody Aldrich Partners LLC Has $1.25 Million Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Reassessing Viridian Therapeutics (VRDN) Valuation Following Insider Buying and Progress in Thyroid Eye Disease Program - Sahm
Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors - Barron's
Fairmount Funds Management LLC's Strategic Acquisition in Viridi - GuruFocus
Wedbush Reduces Earnings Estimates for Viridian Therapeutics - MarketBeat
How supply chain issues affect Viridian Therapeutics Inc. stock2025 Top Decliners & Free High Return Stock Watch Alerts - newser.com
How Viridian Therapeutics Inc. stock performs in interest rate cyclesEarnings Miss & Consistent Growth Stock Picks - newser.com
Is Viridian Therapeutics Inc. (1S1) stock a buy on weaknessTrade Volume Report & Real-Time Volume Surge Alerts - newser.com
Using Ichimoku Cloud for Viridian Therapeutics Inc. technicalsEarnings Overview Report & Short-Term High Return Ideas - newser.com
Finanzdaten der Viridian Therapeutics Inc-Aktie (VRDN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):